Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tecsys Inc T.TCS

Alternate Symbol(s):  TCYSF

Tecsys Inc. is a Canada-based company, which is a global provider of advanced supply chain solutions. The Company’s principal business activity is the development, marketing and sale of enterprise-wide supply chain management software for distribution, warehousing, transportation logistics, point-of-use and order management. It also provides related consulting, education and support services. It operates through the development and marketing of enterprise-wide distribution software and related services segment. Its supply chain solutions include Elite Enterprise, Elite Healthcare, Omni Retail and Streamline. The Tecsys Itopia platform is the technology infrastructure on which its Elite Enterprise suite of supply chain applications is built. It offers a range of services including implementation, support services, system enhancement, cloud services and advisory services. Its cloud solutions serve a diverse range of industries, including healthcare, distribution and converging commerce.


TSX:TCS - Post by User

Post by retiredcfon Jul 03, 2024 6:15am
128 Views
Post# 36115795

Another Earnings Assessment

Another Earnings AssessmentNot so bad. GLTA

EPS of $0.02 missed estimates of $0.0583 and revenues of $43.96M missed estimates of $44.81M. Sales grew by 7%, but its SaaS revenue grew by 27% for the quarter, and its SaaS subscription bookings grew by 108%. Gross margins increased to 47% from 45% in the prior year, and management updated guidance for FY2025 calling for 7% to 9% revenue growth, 30% to 32% SaaS revenue growth and 8% to 9% Adjusted EBITDA margins. It has a solid sales pipeline and management is emphasizing on refining its SaaS software, deepening its healthcare vertical, and expanding its footprint in the European markets. Overall, these were decent results and the stock is reacting positively to the numbers and guidance. (5iResearch)
<< Previous
Bullboard Posts
Next >>